Skip to content
Study details
Enrolling now

Imaging Depression in Parkinson's Disease

Yale University
NCT IDNCT06402955ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

120

Study length

about 4.1 years

Ages

40–80

Locations

1 site in CT

What this study is about

Researchers are testing whether imaging can help identify the brain areas that cause depression in people with Parkinson's disease. The trial will use scans to look at how different parts of the brain are working when people experience depression. It involves adults aged 40-80 experiencing symptoms of depression.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive 11C-UCB-J
  • 2.Take ketamine hydrochloride

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

Anesthetics (Dopamine Agonists)

Endpoints

Primary: Montgomery-Åsberg Depression Rating Scale (MADRS)

Body systems

Neurology, Psychiatry / Mental Health